{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:32:01Z","timestamp":1793071921194,"version":"4.5.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The symptoms of human adenovirus infections are generally mild and self-limiting. However, these infections have been gaining importance in recent years because of a growing number of immunocompromised patients. Solid organ and hematopoietic stem cell transplant patients are subjected to severe immunosuppressive regimes and cannot efficaciously eliminate virus infections. In these patients, adenovirus infections can develop into deadly multi-organ disseminated disease. Presently, in the absence of approved therapies, physicians rely on drugs developed for other purposes to treat adenovirus infections. As there is a need for anti-adenoviral therapies, researchers have been developing new agents and repurposing existing ones to treat adenovirus infections. There are several small molecule drugs that are being tested for their efficacy against human adenoviruses; some of these have reached clinical trials, while others are still in the preclinical phase. Besides these compounds, research on immunotherapy against adenoviral infection has made significant progress, promising another modality for treatment. The availability of an animal model confirmed the activity of some drugs already in clinical use while proving that others are inactive. This led to the identification of several lead compounds that await further development. In the present article, we review the current status of anti-adenoviral therapies and their advancement by in vivo studies in the Syrian hamster model.<\/jats:p>","DOI":"10.1093\/femsre\/fuz008","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T20:22:14Z","timestamp":1553545334000},"page":"380-388","source":"Crossref","is-referenced-by-count":34,"title":["Drug development against human adenoviruses and its advancement by Syrian hamster models"],"prefix":"10.1093","volume":"43","author":[{"given":"William S M","family":"Wold","sequence":"first","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, 1100 S. Grand Boulevard, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, 1100 S. Grand Boulevard, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, 1100 S. Grand Boulevard, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline F","family":"Spencer","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, 1100 S. Grand Boulevard, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoly","family":"Toth","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, 1100 S. Grand Boulevard, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"2021041200430250100_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/15257770.2015.1034363","article-title":"Synthesis and comparative study of anti-adenoviral activity of 6-azacytidine and its analogues","volume":"34","author":"Alexeeva","year":"2015","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2021041200430250100_bib3","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00203-10","article-title":"Small-molecule screening using a whole-cell viral replication reporter gene assay identifies 2-{[2-(benzoylamino)benzoyl]amino}-benzoic acid as a novel antiadenoviral compound","volume":"54","author":"Andersson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041200430250100_bib4","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000002090","article-title":"Successful brincidofovir treatment of metagenomics-detected adenovirus infection in a severely ill STAT1-deficient patient","author":"Averbuch","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2021041200430250100_bib5","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"2021041200430250100_bib6","first-page":"1704","article-title":"Adenoviridae","volume-title":"Fields Virology","author":"Berk","year":"2013"},{"key":"2021041200430250100_bib7","first-page":"295","article-title":"Adenovirus infection in a renal transplant patient","volume":"24","author":"Blohme","year":"1992","journal-title":"Transplant Proc"},{"key":"2021041200430250100_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2016.07.021","article-title":"The use of brincidofovir for the treatment of mixed dsDNA viral infection","volume":"83","author":"Camargo","year":"2016","journal-title":"J Clin Virol"},{"key":"2021041200430250100_bib9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01925-18","article-title":"Cidofovir diphosphate inhibits adenovirus 5 DNA polymerase via both non-obligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus","author":"Chamberlain","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041200430250100_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1700997","article-title":"Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir","volume":"20","author":"Chen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2021041200430250100_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1167\/iovs.10-5944","article-title":"Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis","volume":"52","author":"Clement","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021041200430250100_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2021041200430250100_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/cgt.2014.13","article-title":"Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters","volume":"21","author":"Dhar","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"2021041200430250100_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9343(97)85997-9","article-title":"Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient","volume":"103","author":"Duggan","year":"1997","journal-title":"Am J Med"},{"key":"2021041200430250100_bib15","doi-asserted-by":"crossref","first-page":"e109755","DOI":"10.1371\/journal.pone.0109755","article-title":"Efficient gene targeting in golden Syrian hamsters by the CRISPR\/Cas9 system","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"key":"2021041200430250100_bib16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"2021041200430250100_bib17","article-title":"Brincidofovir was used to successfully treat adenovirus infections in solid organ transplant recipients and other immunocompromised patients","author":"Florescu","year":"2018","journal-title":"American Transplant Congress"},{"key":"2021041200430250100_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/INF.0000000000000487","article-title":"Cidofovir in pediatric solid organ transplant recipients: University of Nebraska experience","volume":"34","author":"Florescu","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2021041200430250100_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"Florescu","year":"2014","journal-title":"Expert Rev of AntiInfect Ther"},{"key":"2021041200430250100_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021041200430250100_bib21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nature Med"},{"key":"2021041200430250100_bib22","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"2021041200430250100_bib23","first-page":"574","article-title":"An ocular model of adenovirus type 5 infection in the NZ rabbit","volume":"33","author":"Gordon","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021041200430250100_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0166-3542(91)90054-U","article-title":"Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro","volume":"16","author":"Gordon","year":"1991","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.11.136","article-title":"Preliminary results from the AdVise study evaluating brincidofovir (BCV, CMX001) for the treatment of disseminated and high-risk adenovirus (AdV) infection","author":"Grimley","year":"2015","journal-title":"Bone Marrow Transplant Tandem Meetings"},{"key":"2021041200430250100_bib26","article-title":"Improved outcomes in allogeneic hematopoietic cell transplant (allo HCT) patients treated with brincidofovir for disseminated adenovirus (AdV) disease compared to literature: Updated preliminary results from the AdVise (CMX001-304) study","author":"Grimley","year":"2015","journal-title":"41st Annual Meeting of the European Society for Blood and Marrow Transplantation"},{"key":"2021041200430250100_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: A randomized placebo-controlled Phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021041200430250100_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01623-16","article-title":"Suppression of Adenovirus Replication by Cardiotonic Steroids","volume":"91","author":"Grosso","year":"2017","journal-title":"J Virol"},{"key":"2021041200430250100_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev"},{"key":"2021041200430250100_bib30","first-page":"99","article-title":"Synthesis and antiviral evalution of some novel pyrazoles and pyrazolo[3,4-d]pyridazines bearing 5,6,7,8-tetrahydronaphthalene","volume":"70","author":"Hamdy","year":"2013","journal-title":"Acta Pol Pharm"},{"key":"2021041200430250100_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J Infect Dis"},{"key":"2021041200430250100_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.antiviral.2018.09.015","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses","volume":"159","author":"Hartline","year":"2018","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib33","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"key":"2021041200430250100_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF01487691","article-title":"A new hamster model for adenoviral vaccination","volume":"100","author":"Hjorth","year":"1988","journal-title":"Arch Virol"},{"key":"2021041200430250100_bib35","first-page":"33","article-title":"Stereospecific syntheses of 9-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA)","volume":"18","author":"Holy","year":"1987","journal-title":"Nucleic Acids Symp Ser"},{"key":"2021041200430250100_bib36","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib37","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","article-title":"A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations","volume":"59","author":"Hutterer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041200430250100_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2012.10.008","article-title":"An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs","volume":"97","author":"Ibrisimovic","year":"2013","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1472-6750-13-54","article-title":"Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovir","volume":"13","author":"Ibrisimovic","year":"2013","journal-title":"BMC Biotechnol"},{"key":"2021041200430250100_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/9781555819040.ch10","article-title":"Adenovirus","volume-title":"Diagnostic Microbiology of the Immunocompromised Host","author":"Ison","year":"2016","edition":"2nd Edition"},{"key":"2021041200430250100_bib40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/505498","article-title":"Adenovirus infections in transplant recipients","volume":"43","author":"Ison","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021041200430250100_bib42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1086\/519938","article-title":"Outbreak of human adenovirus type 3 infection in a pediatric long-term care facility\u2013Illinois, 2005","volume":"45","author":"James","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021041200430250100_bib43","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","article-title":"Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species","volume":"80","author":"Jogler","year":"2006","journal-title":"J Virol"},{"key":"2021041200430250100_bib44","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmcl.2016.09.071","article-title":"First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via \u2018privileged scaffold\u2019 refining approach","volume":"26","author":"Kang","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"2021041200430250100_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1515\/jcim-2016-0050","article-title":"Anti-adenovirus activity, antioxidant potential, and phenolic content of black tea (Camellia sinensis Kuntze) extract","volume":"13","author":"Karimi","year":"2016","journal-title":"J Complement Integr Med"},{"key":"2021041200430250100_bib46","first-page":"796","article-title":"Cellular immune therapy for viral infections in transplant patients","volume":"138","author":"Khanna","year":"2013","journal-title":"Indian J Med Res"},{"key":"2021041200430250100_bib47","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00390-18","article-title":"Hacking the cell: network intrusion and exploitation by Adenovirus E1A","volume":"9","author":"King","year":"2018","journal-title":"mBio"},{"key":"2021041200430250100_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.03.011","article-title":"Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery","volume":"94","author":"Kneidinger","year":"2012","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2018.08.004","article-title":"Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro","volume":"158","author":"Kumaki","year":"2018","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1196\/annals.1358.013","article-title":"T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients","volume":"1062","author":"Leen","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2021041200430250100_bib51","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"2021041200430250100_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2006.04.007","article-title":"Antiviral therapy for adenovirus infections","volume":"71","author":"Lenaerts","year":"2006","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/380450","article-title":"Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection","volume":"38","author":"Leruez-Ville","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021041200430250100_bib54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/08830180490265556","article-title":"Functions and mechanisms of action of the adenovirus E3 proteins","volume":"23","author":"Lichtenstein","year":"2004","journal-title":"Int Rev Immunol"},{"key":"2021041200430250100_bib56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/leu.2010.4","article-title":"Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation","volume":"24","author":"Lion","year":"2010","journal-title":"Leukemia"},{"key":"2021041200430250100_bib55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2021041200430250100_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virusres.2012.12.001","article-title":"Dioscin's antiviral effect in vitro","volume":"172","author":"Liu","year":"2013","journal-title":"Virus Res"},{"key":"2021041200430250100_bib58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbmt.2014.10.012","article-title":"The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution","volume":"21","author":"Lugthart","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021041200430250100_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41598-018-37290-3","article-title":"Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections","volume":"9","author":"Marrugal-Lorenzo","year":"2019","journal-title":"Sci Rep"},{"key":"2021041200430250100_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2018.09.011","article-title":"Inhibition of adenovirus infection by mifepristone","volume":"159","author":"Marrugal-Lorenzo","year":"2018","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib61","doi-asserted-by":"crossref","first-page":"40472","DOI":"10.1038\/srep40472","article-title":"De novo assembly, annotation, and characterization of the whole brain transcriptome of male and female Syrian hamsters","volume":"7","author":"McCann","year":"2017","journal-title":"Sci Rep"},{"key":"2021041200430250100_bib62","doi-asserted-by":"publisher","DOI":"10.3390\/v10050243","article-title":"Characterization of an N-terminal non-core domain of RAG1 gene disrupted Syrian hamster model generated by CRISPR Cas9","volume":"10","author":"Miao","year":"2018","journal-title":"Viruses"},{"key":"2021041200430250100_bib63","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ardp.201400387","article-title":"Novel antiviral compounds against gastroenteric viral infections","volume":"348","author":"Mohamed","year":"2015","journal-title":"Arch Pharm (Weinheim)"},{"key":"2021041200430250100_bib64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/135965350901400110","article-title":"Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone","volume":"14","author":"Morfin","year":"2009","journal-title":"Antiviral Ther"},{"key":"2021041200430250100_bib65","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2021041200430250100_bib66","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"O'Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2021041200430250100_bib67","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1021\/jm201636v","article-title":"Synthesis, biological evaluation, and structure\u2013activity relationships of 2-[2-(benzoylamino)benzoylamino]benzoic acid analogues as inhibitors of adenovirus replication","volume":"55","author":"\u00d6berg","year":"2012","journal-title":"J Med Chem"},{"key":"2021041200430250100_bib68","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041200430250100_bib69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcv.2010.10.016","article-title":"Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001","volume":"50","author":"Paolino","year":"2011","journal-title":"J Clin Virol"},{"key":"2021041200430250100_bib70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"2021041200430250100_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2015.05.010","article-title":"Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir","volume":"120","author":"Pozzuto","year":"2015","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib72","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.bbmt.2017.01.062","article-title":"Treatment of adenovirus (AdV) infection in allogeneic hematopoietic cell transplant (allo HCT) patients (pts) with brincidofovir: Final 36 week results from the Advise trial","volume":"23","author":"Prasad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021041200430250100_bib73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/JVI.67.1.101-111.1993","article-title":"Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus)","volume":"67","author":"Prince","year":"1993","journal-title":"J Virol"},{"key":"2021041200430250100_bib74","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1128\/JVI.01790-15","article-title":"Low-level expression of the E1B 20-kilodalton protein by adenovirus 14p1 enhances viral immunopathogenesis","volume":"90","author":"Radke","year":"2015","journal-title":"J Virol"},{"key":"2021041200430250100_bib75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2016.01.005","article-title":"Haploidentical bone marrow and stem cell transplantation: Experience with post-transplantation cyclophosphamide","volume":"53","author":"Robinson","year":"2016","journal-title":"Semin Hematol"},{"key":"2021041200430250100_bib76","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ajo.2008.07.030","article-title":"Update on antiviral treatment of adenoviral ocular infections","volume":"146","author":"Romanowski","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"2021041200430250100_bib77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.15585\/mmwr.mm6712a6","article-title":"Notes from the field: fatalities associated with human adenovirus type 7 at a substance abuse rehabilitation facility - New Jersey, 2017","volume":"67","author":"Rozwadowski","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021041200430250100_bib78","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1021\/acs.jmedchem.6b00300","article-title":"New 4-Acyl-1-phenylaminocarbonyl-2-phenylpiperazine derivatives as potential inhibitors of adenovirus infection. synthesis, biological evaluation, and structure-activity relationships","volume":"59","author":"Sanchez-Cespedes","year":"2016","journal-title":"J Med Chem"},{"key":"2021041200430250100_bib79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.antiviral.2014.05.010","article-title":"Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative","volume":"108","author":"Sanchez-Cespedes","year":"2014","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib80","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: Current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Curr Infect Dis Reports"},{"key":"2021041200430250100_bib81","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtn.2017.07.002","article-title":"Anti-adenoviral artificial microRNAs expressed from AAV9 vectors inhibit human adenovirus infection in immunosuppressed Syrian hamsters","volume":"8","author":"Schaar","year":"2017","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"2021041200430250100_bib82","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3851\/IMP3047","article-title":"Biological antivirals for treatment of adenovirus infections","volume":"21","author":"Schaar","year":"2016","journal-title":"Antivir Ther"},{"key":"2021041200430250100_bib83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.753","article-title":"Incidence of adenovirus infection in hematopoietic stem cell transplantation recipients: Findings from the AdVance study","author":"Sedlacek","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021041200430250100_bib84","first-page":"203","article-title":"Management of respiratory viral infections in hematopoietic cell transplant recipients","volume":"2","author":"Shah","year":"2012","journal-title":"Am J of Blood Research"},{"key":"2021041200430250100_bib1","author":"State of New Jersey Department of Health"},{"key":"2021041200430250100_bib85","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/mt.2008.162","article-title":"Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model","volume":"16","author":"Thomas","year":"2008","journal-title":"Mol Ther"},{"key":"2021041200430250100_bib86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1 (Oat1)","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2021041200430250100_bib88","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/JVI.70.4.2296-2306.1996","article-title":"The adenovirus death protein (E3-11.6\u00a0K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells","volume":"70","author":"Tollefson","year":"1996","journal-title":"J Virol"},{"key":"2021041200430250100_bib89","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib90","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00284-17","article-title":"Pathology in permissive Syrian hamsters after infection with species C human adenovirus (HAdV-C) is the result of virus replication: HAdV-C6 replicates more and causes more pathology than HAdV-C5","volume":"91","author":"Tollefson","year":"2017","journal-title":"J Virol"},{"key":"2021041200430250100_bib92","doi-asserted-by":"crossref","first-page":"e1005084","DOI":"10.1371\/journal.ppat.1005084","article-title":"STAT2 knockout Syrian hamsters support enhanced replication and pathogenicity of human adenovirus, revealing an important role of type I interferon response in viral control","volume":"11","author":"Toth","year":"2015","journal-title":"PLoS Pathog"},{"key":"2021041200430250100_bib91","article-title":"USC-087 and USC-505 protect immunosuppressed Syrian hamsters against lethal intravenous challenge with human type 5 and 6 adenoviruses","author":"Toth","year":"2016","journal-title":"29th International Conference on Antiviral Research"},{"key":"2021041200430250100_bib93","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021041200430250100_bib95","doi-asserted-by":"publisher","DOI":"10.3390\/v9060147","article-title":"HAdV-C6 is a more relevant challenge virus than HAdV-C5 for testing antiviral drugs with the immunosuppressed Syrian hamster model","volume":"9","author":"Toth","year":"2017","journal-title":"Viruses"},{"key":"2021041200430250100_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.03.001","article-title":"USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses","volume":"153","author":"Toth","year":"2018","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib96","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2017.08.002","article-title":"Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds","volume":"146","author":"Toth","year":"2017","journal-title":"Antiviral Res"},{"key":"2021041200430250100_bib97","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/v7031409","article-title":"Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters","volume":"7","author":"Toth","year":"2015","journal-title":"Viruses"},{"key":"2021041200430250100_bib98","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.virol.2005.06.021","article-title":"Acute respiratory infection with mouse adenovirus type 1","volume":"340","author":"Weinberg","year":"2005","journal-title":"Virology"},{"key":"2021041200430250100_bib99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Chapter three\u2013Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv Cancer Res"},{"key":"2021041200430250100_bib100","first-page":"1732","article-title":"Adenoviruses","volume-title":"Fields Virology","author":"Wold","year":"2013"},{"key":"2021041200430250100_bib101","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2017.10.015","article-title":"Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females","volume":"514","author":"Ying","year":"2018","journal-title":"Virology"},{"key":"2021041200430250100_bib102","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041200430250100_bib104","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/cgt.2009.6","article-title":"INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: Comparison of biodistribution studies","volume":"16","author":"Ying","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"2021041200430250100_bib103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2015.07.024","article-title":"Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters","volume":"485","author":"Ying","year":"2015","journal-title":"Virology"},{"key":"2021041200430250100_bib105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/01.tp.0000209195.95115.8e","article-title":"Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients","volume":"81","author":"Yusuf","year":"2006","journal-title":"Transplantation"},{"key":"2021041200430250100_bib106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/cgt.2014.64","article-title":"A novel immunocompetent murine model for replicating oncolytic adenoviral therapy","volume":"22","author":"Zhang","year":"2015","journal-title":"Cancer Gene Ther"}],"container-title":["FEMS Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/femsre\/article-pdf\/43\/4\/380\/37020738\/fuz008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femsre\/article-pdf\/43\/4\/380\/37020738\/fuz008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T10:11:39Z","timestamp":1663150299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femsre\/article\/43\/4\/380\/5420752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":105,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,3,27]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/femsre\/fuz008","relation":{},"ISSN":["1574-6976"],"issn-type":[{"value":"1574-6976","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,3,27]]}}}